Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Matrix Metalloproteinases (MMPs) are enzymes that degrade the extracellular matrix (ECM).
• First discovered in tadpole metamorphosis, MMPs are now known to be involved in various physiological and pathological processes.
• Dysregulation of MMPs is implicated in numerous human diseases, including arthritis and cancer.

Purpose of the Study:

• To review current intervention strategies targeting MMPs.
• To explore novel therapeutic approaches for MMP inhibition.
• To highlight the potential of monoclonal antibodies as MMP inhibitors.

Main Methods:

• Literature review of existing research on MMP inhibitors.
• Analysis of direct and indirect MMP activation blocking strategies.
• Exploration of monoclonal antibody-based therapeutic concepts.

Main Results:

• A broad family of MMPs has been identified, with significant roles in disease.
• Various inhibitory compounds targeting MMPs have been developed.
• Monoclonal antibodies represent a promising avenue for future MMP inhibitor development.

Conclusions:

• MMPs play a critical role in cancer invasion and metastasis.
• Targeting MMPs offers a therapeutic strategy for cancer and other diseases.
• Further research into MMP inhibitors, particularly monoclonal antibodies, is warranted.